Merck’s COVID-19 Pill Significantly Less Effective in New Analysis

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via Reuters
An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via Reuters
TT

Merck’s COVID-19 Pill Significantly Less Effective in New Analysis

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via Reuters
An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via Reuters

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.

The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. In October, its data showed a roughly 50% efficacy, based on data from 775 patients. The drug, molnupiravir, was developed with partner Ridgeback Biotherapeutics.

The lower efficacy of Merck's drug could have big implications in terms of whether countries continue to buy the pill. Interim data from 1,200 participants in Pfizer Inc's trial for its experimental pill, Paxlovid, showed an 89% reduction in hopsitalizations and deaths.

Merck's shares fell 3.5% to $79.39 in morning trading.

Merck released the data before the US Food and Drug Administration published a set of documents on Friday intended to brief a panel of outside experts who will meet on Tuesday to discuss whether to recommend authorizing the pill.

The agency's staff did not make their own recommendation as to whether the pill should be authorized.

FDA staff asked the panel to discuss whether the benefits of the drug outweigh the risks and whether the population for whom the drug should be authorized should be limited.

They also asked the committee to weigh in on concerns over whether the drug could encourage the virus to mutate, and how those concerns could be mitigated.

Pills like molnupiravir and Paxlovid could be promising new weapons in the fight against the pandemic, as they can be taken as early at-home treatments to help prevent COVID-19 hospitalizations and deaths. They could also become important tools in countries and areas with limited access to vaccines or low inoculation rates.

Easier treatment

The Merck and Pfizer pills are cheaper to produce and easier to administer than existing treatment options such as antibody therapies from Regeneron and Eli Lilly, which are mostly administered as intravenous infusions.

The two experimental drugs have different mechanisms of action. Merck's is designed to introduce errors into the genetic code of the virus. Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck filed for a US authorization of molnupiravir on Oct. 11, following the interim data, and submitted the updated data to the FDA this week.

The molnupiravir arm of the study had a hospitalization and death rate of 6.8%, according to the updated data. The placebo group had a hospitalization and death rate of 9.7%.

One patient in the molnupiravir arm died, versus nine in the placebo group.

The United Kingdom conditionally approved molnupiravir, branded as Lagevrio, earlier this month.

Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022. It has a contract with the US government to supply as many as 5 million courses at a price of $700 per course. Several other countries have already secured millions of courses of the pill.

Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age also had to use birth control.

Still, the FDA said in its briefing document that there are safety concerns about potential birth defects from the drug and asked the panel to discuss whether the drug should be available to pregnant women.



Trump Says Takes ‘Very Seriously’ Possible Iran Threat to Washington

 An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
TT

Trump Says Takes ‘Very Seriously’ Possible Iran Threat to Washington

 An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)
An aerial view of Washington, DC is seen on October 13. (AFP/Getty Images)

President Donald Trump said Tuesday that US authorities take "very seriously" any possible threat to Washington, after reports of Iran preparing a so-called dirty bomb plot.

"They will pay a price the likes of which no other country has ever paid before," Trump said, referring to Iran. "We take it very seriously because they happen to be crazy."

Earlier on Tuesday, Iran's Foreign Ministry spokesperson denied a CNN report that it ‌planned to ‌detonate a dirty ‌bomb ⁠in Washington, saying ⁠the allegations were "baseless".

CNN ‌cited ‌sources as saying that US intelligence ‌indicates that Tehran is developing ⁠plans ⁠to potentially detonate a dirty bomb in Washington DC.

Sources familiar with the latest intelligence characterized the Iranian planning as, for now, an effort to give itself options rather than an indicator of an imminent attack, reported CNN. But the plotting picked up by the US has been very specific and includes locations and targets, two of the sources said, and has sparked a flurry of US contingency planning.  

In a statement, White House spokesperson Lauren Bis said that the US is “monitoring any and all potential threats, but at this time there are no credible threats to the homeland.” 


Trump Arrives in Manila for Quad Talks Ahead of China Visit

US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
TT

Trump Arrives in Manila for Quad Talks Ahead of China Visit

US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)
US President Donald Trump waves as he walks to board Air Force One at Joint Base Andrews, Maryland, on November 16, 2026. (AFP)

US President Donald Trump arrived in the Philippines on Tuesday at the tail end of a Southeast Asian summit, with protests awaiting him as he prepares for the first meeting in two years of the Quad group of Indo-Pacific countries.

Trump's Asia trip, which includes the Asia-Pacific Economic Cooperation (APEC) forum in Shenzhen and a much-anticipated trilateral meeting with his Chinese and Russian counterparts, comes after his Republican Party's defeat in midterm elections, plus spy allegations and new US curbs on China's access to AI chips that could complicate a fragile trade-war truce.

Demonstrators gathered in Manila for a fifth day of protests that have included the burning of Trump effigies, calls for an end to the Middle East war and scrapping of the US-led Pax Silica supply chain initiative.

Trump arrived late afternoon at the end of the Association of Southeast Asian Nations summit ‌and will join a ‌US-ASEAN "Special Summit" later on Tuesday.

He will first hold a meeting of the Quad – ‌the ⁠US, Japan, Australia and ⁠India – which will be his first and takes place two years after the last gathering of the group, which Trump's predecessor Joe Biden regarded as a signature foreign policy initiative.

It comes ahead of the APEC gathering hosted by Chinese President Xi Jinping, who has previously objected to the Quad as an effort to encircle Beijing. Quad members have said the grouping is not directed against any one country.

QUAD MEETING THE 'BEST POSSIBLE SIGNAL'

At the ASEAN summit on Monday, Chinese Premier Li Qiang hailed what he called "truly extraordinary" economic achievements of China and ASEAN in the face of global trade restrictions, expressing Beijing's commitment to free trade and the need to "stand united, ward off interference, and work together".

China ⁠is ASEAN's largest trading partner and a key source of investment, but the biggest economies ‌of the 11-member bloc – which has a combined GDP of more than $3.9 trillion – ‌want to deepen ties with the US despite protracted trade and diplomatic uncertainty under the Trump administration.

Former US Deputy Secretary of State Kurt ‌Campbell credited Washington's top diplomat, Marco Rubio, with the timing and reconvening of the Quad, which he said had lost ambition ‌under Trump.

"Part of what he (Rubio) is thinking is that this is probably the best possible signal if you're going to go into a trilateral meeting," said Campbell, co-founder of The Asia Group, referring to Thursday's US-China-Russia talks.

"The linchpin of everything that we do in Asia is the US-Japan relationship, and a perception that this is not at the top of the president's mind would concern me."

White House spokesperson Olivia Wales on Friday ‌said that under Trump's leadership, the Quad had demonstrated it is "a partnership of action, tackling the region's toughest challenges and driving opportunities to ensure a free and open Indo-Pacific".

A Japanese foreign ⁠ministry official said it was ⁠expected that Quad leaders would try to show unity, with maritime security, export restrictions, critical-minerals supply-chain diversification and AI among potential discussion points.

Undersea cables, emerging technology and disaster relief were also likely to be covered, a source familiar with the matter said.

JAPAN TO PLAY MORE PROACTIVE ROLE, PM SAYS

ASEAN's leaders held meetings on Tuesday involving counterparts of Japan, South Korea, China and India.

Japanese Prime Minister Sanae Takaichi pledged to work with ASEAN to boost regional economic and energy resilience to address export restrictions and vulnerabilities from rapid AI development, and strengthen supply chains, including on critical minerals.

"While the international order is experiencing a period of great instability, Japan will play an ever more proactive role," Takaichi said.

Trump will sign a joint statement with Thai Prime Minister Anutin Charnvirakul on Tuesday on an agreement on reciprocal trade. Thai media have reported the two would hold talks and the statement would be about progress on negotiations.

The US is Thailand's largest export market, accounting for 24% of its total shipments this year. The US designated Thailand as a major non-NATO ally in 2003.

Trump will on Wednesday meet Ferdinand Marcos Jr, president of US defense ally the Philippines, before heading to Shenzhen.


Pakistan Army Chief and Iran FM Discuss Regional Peace, Security

Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
TT

Pakistan Army Chief and Iran FM Discuss Regional Peace, Security

Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)
Vessels at the Strait of Hormuz, as seen from Musandam, Oman, November 17, 2026. (Reuters)

Asim Munir, the powerful army chief of mediating country Pakistan, met with Iranian foreign minister Abbas Araghchi, the Pakistani military said Tuesday, during continued efforts to end the war between the United States and Iran.

Pakistan brokered a June accord that led to a brief halt in fighting between the United States and Iran and set a roadmap for further agreement on reopening the crucial Strait of Hormuz waterway and for negotiations on Tehran's nuclear program.

But the truce collapsed with Washington and Tehran accusing each other of violating the agreement and prompting months of shuttle diplomacy to resuscitate the ceasefire, led principally by mediators Qatar and Pakistan.

During the meeting on Monday, "matters of mutual interest, regional security dynamics and evolving geopolitical developments were discussed," the Pakistani military's media wing said in a statement.

Munir "underscored the importance of sustained engagement, mutual trust and close coordination between the two brotherly countries for promoting regional peace and stability", it added.

Araghchi arrived in Pakistan late on Sunday for a meeting of the Economic Cooperation Organization, a group of nations from Central and South Asia and the Middle East.

Pakistani Foreign Minister Ishaq Dar said on Monday he had held "very candid, very frank" discussions with Araghchi, during the conference confirming that Iran had put forward a two-day proposal to reopen the Strait of Hormuz as part of efforts to end the war with the United States.

He said Washington had not yet responded.

The United States and Israel launched the war on February 28, killing members of Iran's leadership and demanding it cease any nuclear-related activities.

The war plunged the Middle East into violence, with Tehran's retaliatory strikes targeting Gulf countries and sending global energy prices skyrocketing.

Tehran has insisted that Washington meet conditions including the release of frozen assets abroad, sanctions relief and an end to the US naval blockade of Iranian ports in exchange for reopening the Strait of Hormuz.